Joyce O’Shaughnessy

25.8k total citations · 8 hit papers
240 papers, 9.6k citations indexed

About

Joyce O’Shaughnessy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Joyce O’Shaughnessy has authored 240 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 198 papers in Oncology, 125 papers in Pulmonary and Respiratory Medicine and 98 papers in Cancer Research. Recurrent topics in Joyce O’Shaughnessy's work include Cancer Treatment and Pharmacology (121 papers), Advanced Breast Cancer Therapies (108 papers) and HER2/EGFR in Cancer Research (92 papers). Joyce O’Shaughnessy is often cited by papers focused on Cancer Treatment and Pharmacology (121 papers), Advanced Breast Cancer Therapies (108 papers) and HER2/EGFR in Cancer Research (92 papers). Joyce O’Shaughnessy collaborates with scholars based in United States, Spain and United Kingdom. Joyce O’Shaughnessy's co-authors include William J. Gradishar, Paul Bhar, Neil Desai, Sergei Tjulandin, Michael Hawkins, Heather Shaw, Neville Davidson, John Pippen, Denise A. Yardley and Véronique Dièras and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Joyce O’Shaughnessy

227 papers receiving 9.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

2005 1.6k citations Joyce O’Shaughnessy et al. Journal of Clinical Oncology profile →
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

2011 766 citations Véronique Dièras, Igor Bondarenko et al. Journal of Clinical Oncology profile →
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

2011 616 citations Joyce O’Shaughnessy, John Pippen et al. profile →
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

2019 599 citations Aditya Bardia, Sara M. Tolaney et al. profile →
Extending Survival with Chemotherapy in Metastatic Breast Cancer

2005 521 citations Joyce O’Shaughnessy profile →
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

2017 490 citations Maura N. Dickler, Sara M. Tolaney et al. Clinical Cancer Research profile →
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

2024 144 citations Aditya Bardia, Rebecca Dent et al. profile →
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

2024 47 citations Lajos Pusztai, Carsten Denkert et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Joyce O’Shaughnessy

Since Specialization

Citations

This map shows the geographic impact of Joyce O’Shaughnessy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce O’Shaughnessy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce O’Shaughnessy more than expected).

Fields of papers citing papers by Joyce O’Shaughnessy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce O’Shaughnessy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce O’Shaughnessy. The network helps show where Joyce O’Shaughnessy may publish in the future.

Co-authorship network of co-authors of Joyce O’Shaughnessy

This figure shows the co-authorship network connecting the top 25 collaborators of Joyce O’Shaughnessy. A scholar is included among the top collaborators of Joyce O’Shaughnessy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joyce O’Shaughnessy. Joyce O’Shaughnessy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Long-Term Safety and Efficacy of the Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients With HER2-Positive Early Breast Cancer in PHranceSCa, a Randomized, Open-Label Phase II Study	Clinical Breast Cancer	Joyce O’Shaughnessy, Susana Sousa et al.	0
2	Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 breakdown →	Annals of Oncology	Lajos Pusztai, Carsten Denkert et al.	47
3	Ipatasertib plus Paclitaxel for Patients with PIK3CA / AKT1 / PTEN -Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial	Clinical Cancer Research	Rebecca Dent, Sung‐Bae Kim et al.	9
4	Current Clinical Utility of Circulating Tumor DNA Testing in Breast Cancer: A Practical Approach	JCO Oncology Practice	Jing Xi, X. Cynthia et al.	2
5	Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study	Journal of the National Comprehensive Cancer Network	Tara Sanft, Rachel C. Jankowitz et al.	1
6	Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1 -Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups	Clinical Cancer Research	Aditya Bardia, Javier Cortés et al.	33
7	274P Impact of dose reductions on efficacy of adjuvant abemaciclib for patients with high-risk early breast cancer (EBC): Analyses from the monarchE study	Annals of Oncology	Joyce O’Shaughnessy, Laura Testa et al.	1
8	Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2− Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7	Clinical Cancer Research	Aleix Prat, Nadia Solovieff et al.	8
9	97P Efficacy and safety of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer: Long-term data from the PHranceSCa study	ESMO Open	Joyce O’Shaughnessy, Josefina Cruz Jurado et al.	1
10	Phase I Trial of a Novel Anti-HER2 Antibody–Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer	Clinical Cancer Research	Jian Zhang, Dongmei Ji et al.	49
11	Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study	Clinical Cancer Research	Antoinette R. Tan, Gail S. Wright et al.	28
12	Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis	Scientific Reports	Joyce O’Shaughnessy, Javier Cortés et al.	8
13	Real-world survival outcomes of heavily pretreated patients with refractory HR+, HER2−metastatic breast cancer receiving single-agent chemotherapy—a comparison with MONARCH 1	Breast Cancer Research and Treatment	Hope S. Rugo, Véronique Dièras et al.	3
14	LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)	Annals of Oncology	D.W. Miles, Joseph Gligorov et al.	74
15	Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers	Molecular Cancer Research	Timothy R. Wilson, Akshata R. Udyavar et al.	15
16	Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib + letrozole: Results from MONALEESA-2.	Journal of Clinical Oncology	Sunil Verma, Joyce O’Shaughnessy et al.	9
17	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer breakdown →	Clinical Cancer Research	Maura N. Dickler, Sara M. Tolaney et al.	490
18	Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine	Clinical Cancer Research	Joyce O’Shaughnessy, Hartmut Koeppen et al.	37
19	Highlights in metastatic breast cancer From the 2012 San Antonio Breast Cancer Symposium (SABCS).	Québec français	Joyce O’Shaughnessy	2
20	Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735	Journal of Clinical Oncology	Stephen E. Jones, Frankie A. Holmes et al.	400

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact